Sana Biotechnology
Sana Biotechnology develops engineered cell and gene therapies to repair, control, or replace cells in order to address the underlying causes of diseases such as diabetes, B-cell cancers, and B-cell related autoimmune disorders. Its mission is to create novel medicines that meaningfully improve patient outcomes and broaden access to transformative treatments.
Facts
- Sectors
- Biotechnology, Gene editing, Cell therapy, Biopharmaceuticals
- Founded
- 2018 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Sana Biotechnology Inc Seattle business license
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
Sana Biotechnology says SC451 Phase 1/2 and SG293 clinical studies nearing start; Q2 cash $160.5M, runway into mid-2027
Sana Biotechnology reported Q2 2026 progress toward initiating Phase 1/2 trial for SC451 in type 1 diabetes and a clinical study for SG293 in non-Hodgkin lymphoma, highlighted by NEJM publication and upcoming EASD presentation for UP421 clinical data. The company presented SG293 and SG227 preclinical data, advanced a Mayo Clinic collaboration, and reported $160.5M cash with runway into mid-2027.
Sana Biotechnology develops engineered cells to repair genes and replace damaged or missing cells to treat disease
Sana Biotechnology develops engineered cells to repair or control genes and replace missing or damaged cells, aiming to address underlying causes of disease.
Sana Biotechnology Appoints Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA to Board of Directors
Sana Biotechnology appointed three new board members—Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA—to its Board of Directors. The additions expand Sana’s governance as it advances engineered cell therapies.
Sana Biotechnology Appoints Ke Liu, M.D., Ph.D., as Head of Regulatory Affairs & Strategy to Bolster Regulatory Capabilities
Sana Biotechnology has appointed Ke Liu, M.D., Ph.D., as Head of Regulatory Affairs & Strategy to strengthen its regulatory capabilities for engineered cell medicines. Liu brings over 17 years of experience at the U.S. Food and Drug Administration to the senior leadership team.
Sana Biotechnology Announces Acquisition of Oscine Corp. to Expand Engineered Cell Medicines
Sana Biotechnology has acquired Oscine Corp., expanding its efforts to develop engineered cell medicines; the announcement frames the move as part of Sana’s ongoing strategy in cell-engineered therapeutics.
Sana Biotechnology names Ed Rebar, Ph.D. as CTO and Terry Fry, M.D. as SVP, Head of T Cell Therapeutics
Sana Biotechnology appointed Ed Rebar, Ph.D., as Chief Technology Officer and Terry Fry, M.D., as Senior Vice President and Head of T Cell Therapeutics, bolstering its senior research leadership. The hires emphasize Sana’s focus on engineered cell medicines and strengthening scientific expertise.
Sana Biotechnology completes initial financing, raises over $700 million with major institutional investors
Sana Biotechnology completed its initial financing, raising over $700 million and bringing in new institutional shareholders including ARCH Venture Partners, Flagship Pioneering, and the Canada Pension Plan Investment Board.
Sana Biotechnology Releases News and Announcements on Engineering Cells as Medicines
Sana Biotechnology shares news and announcements about its progress in engineering cells to serve as medicines, offering updates on its therapeutic development and company activities.
Sana Biotechnology appoints Stacey Ma, Ph.D. as EVP, Technical Operations to lead global manufacturing and quality
Sana Biotechnology appointed Stacey Ma, Ph.D., as Executive Vice President of Technical Operations to lead process and analytical development, supply chain, quality, and global manufacturing operations.
People
-
Steve Harr Co-founder and President and Chief Executive Officer
-
Snehal Patel Executive, Executive Vice President and Chief Technical Officer